Liquidia (NASDAQ:LQDA) Insider Sarah Krepp Sells 5,245 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sarah Krepp sold 5,245 shares of the business’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $149,377.60. Following the completion of the transaction, the insider owned 115,241 shares in the company, valued at $3,282,063.68. This trade represents a 4.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Down 3.1%

LQDA opened at $26.81 on Wednesday. The business has a 50 day moving average price of $63.40 and a two-hundred day moving average price of $61.76. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. The company has a market cap of $2.40 billion, a PE ratio of 19.57 and a beta of 0.61. Liquidia Corporation has a 52 week low of $21.94 and a 52 week high of $93.61.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The company had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. During the same period in the previous year, the business posted ($0.49) earnings per share. The firm’s revenue was up 1842.1% compared to the same quarter last year. As a group, research analysts anticipate that Liquidia Corporation will post 2.05 EPS for the current year.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Institutional Investors Weigh In On Liquidia

A number of hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its holdings in Liquidia by 18.7% in the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after purchasing an additional 360,372 shares in the last quarter. Eversept Partners LP increased its position in Liquidia by 33.0% during the 1st quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock worth $25,565,000 after purchasing an additional 167,949 shares during the period. Pale Fire Capital SE raised its stake in shares of Liquidia by 2.4% during the 1st quarter. Pale Fire Capital SE now owns 388,377 shares of the company’s stock worth $14,657,000 after buying an additional 8,985 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Liquidia during the 2nd quarter worth approximately $29,694,000. Finally, Seven Fleet Capital Management LP lifted its holdings in shares of Liquidia by 25.2% in the 2nd quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock valued at $20,459,000 after buying an additional 51,727 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on LQDA. Royal Bank Of Canada set a $130.00 price target on Liquidia in a research note on Friday, July 24th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $30.00 price objective (down from $108.00) on shares of Liquidia in a research report on Friday, October 2nd. BTIG Research lowered shares of Liquidia from a “buy” rating to a “neutral” rating in a research report on Thursday, October 1st. Jefferies Financial Group raised shares of Liquidia to a “strong-buy” rating in a research note on Thursday, October 1st. Finally, Stephens set a $130.00 price objective on shares of Liquidia in a research report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $83.69.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).